Chinese startup Harbour BioMed had entered into a license and collaboration agreement with US-based Moderna, a global biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. The strategic collaboration will focus on discovering and developing nucleic acid-based immunotherapies for select oncology targets using the company's proprietary heavy chain only antibody discovery platform (HCAb). Upon the execution of the agreement and subject to terms and conditions thereof, Moderna will be granted an exclusive sub-licensable license to exploit a panel of sequences against multiple targets, derived from the company's HCAb platform, to develop products using nucleic acids. Moderna will assume full responsibility for all upcoming development, manufacturing, regulatory, and commercialization activities. Moderna would also be granted an option to obtain an exclusive sub-licensable license to exploit sequences against additional targets. Pursuant to the agreement, Nona Biosciences (a subsidiary wholly owned by Harbour BioMed) shall receive an upfront payment, and potential milestone payments based on pending achievement of certain regulatory, development, and sales milestones, and tiered royalties.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!